

REGISTERED COMPANY NUMBER: 07564771 (England and Wales)
REGISTERED CHARITY NUMBER: 1141583

GENE PEOPLE

Unaudited Financial Statements for the Year Ended 31 March 2022

Tudor John Limited
Nightingale House
46-48 East Street
Epsom
Surrey
KT17 1HQ

GENE PEOPLE

Contents of the Financial Statements for the year ended 31 March 2022

	Page
Reference and Administrative Details	1
Report of the Trustees	2 to 10
Independent Examiner's Report	11
Statement of Financial Activities	12
Balance Sheet	13
Cash Flow Statement	14
Notes to the Cash Flow Statement	15
Notes to the Financial Statements	16 to 23
Detailed Statement of Financial Activities	24

GENE PEOPLE

Reference and Administrative Details for the year ended 31 March 2022

TRUSTEES	Ms R L Frankel Ms J E Lucas (resigned 29.11.21) Dr C Ruff Mr S Mitra Dr E Miller (resigned 15.11.21) Mr A J Kent Ms E Fernandez-Gonzalez (appointed 11.3.22) (resigned 15.8.22) Mr D Ansel (appointed 10.3.22) Mr C J Conway (appointed 31.3.22) Dr N V Taverner (appointed 19.3.22) Dr D G Atkins (appointed 22.3.22)
REGISTERED OFFICE	Nightingale House 46-48 East Street Epsom Surrey KT17 1HQ
REGISTERED COMPANY NUMBER	07564771 (England and Wales)
REGISTERED CHARITY NUMBER	1141583
INDEPENDENT EXAMINER	Tudor John Limited Nightingale House 46-48 East Street Epsom Surrey KT17 1HQ
SOLICITORS	Stone King, Boundary House, 91 Charterhouse St, Barbican, London, EC1M 6HR
BANKERS	Barclays Corporate, Level 27, 1 Churchill Place, London, E14 5HP

Welcome from the Chair

Re-imagining a charity in the middle of a pandemic is not an obvious course of action. Pushing ahead with the demerger of Genetic Disorders UK from Jeans for Genes and PID UK might have sensibly been put on the back burner until things quietened down. But we had a vision. We knew that the needs of people living with the daily consequences of genetic conditions would not wait until “things quietened down”.

So, we decided to act. Gene People is the result.

Our focus is relentlessly on the needs of patients and families. We work with them directly through our unique genetic counsellor-led helpline, where we are in daily contact with people struggling to get or understand a diagnosis. We work closely with colleagues in the NHS and elsewhere to try and ensure that families coming to terms with a genetic condition can make plans on how to face the future and are aware of the help they can access.

Families often turn to support groups for that help. These groups are an invaluable source of expert knowledge, usually based on the experience of affected families. Many of these groups share common problems – how to organize? Where do I go to find out how to access expert help and support? How can I fundraise?

Gene People has initiated a capacity building programme for the partners in the Partnership Network. Workshops and shared learning opportunities have been initiated. This programme will grow as more resources become available.

Gene People has reached out to policy makers, politicians, the NHS and industry to make them aware of the needs and opinions of our community. We have responded to a range of consultations, working in cross-sectoral partnerships, making direct inputs where opportunities have arisen and presenting at national and international meetings – always prioritizing the needs and opinions drawn directly from our engagement with our partners and those they represent.

We are making an impact. We will continue to do so, and we welcome collaboration and support from all those who share our vision.

Finally, I must pay tribute to our fantastic staff, and thank my trustee colleagues for their hard work, their commitment and their insights, without which the decision we made a year ago would not have brought us to the position we are in today, facing a future with growing confidence and a clear vision of how we can make a difference.



Alastair Kent OBE FRSA
Chair of Trustees

GENE PEOPLE

"It is absolutely lovely that you call people back again to see how they are doing and I really appreciate it. It's a fantastic service."
- Helpline caller

174 enquirers contacted the Helpline

5,507 Twitter followers

5,573 Facebook followers

134 Partnership Network members

Report of the Board of Trustees for the year ended 31 March 2022

The trustees who are also directors of the charity for the purposes of the Companies Act 2006, present their report with the financial statements of the charity for the year ended 31 March 2022. The trustees have adopted the provisions of Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019).

Our Aims and Objectives

Gene People was founded in 2011 as Genetic Disorders UK with the vision of improving the lives of those affected by a genetic disorder through the provision of resources and support both to individuals and families, and to the hundreds of disorder-specific charities and patient groups that have been established in the UK.

The objectives of the charity are:

- To raise awareness and advance the education of the public on the subject of genetic disorders
- The relief of persons suffering from genetic disorders
- The advancement of medical research into the causes, cure, prevention or relief of such disorders and the publication of results of that research
- To promote the efficiency and effectiveness of other genetic disorder charities so they may achieve their charitable purposes.

We serve two distinct audiences:

- Those affected by a genetic condition, their families and carers, and support universe
- Condition-specific support groups and charities.

Activities

Trustees were keen that the financial year 2021-22 saw the continuation of the **change programme** begun in the previous year. The name of the charity changed in June 2021 to Gene People and included a new look and feel for the charity. The charity was restructured to be leaner and more agile. There were more changes after the period of this report with the team currently consisting of the full-time chief executive and the part time genetic counsellor, with outsourced input on IT, the website, communications and accountancy.

A major part of the change programme was to create a new strategy for the coming three years. The team met with the Chair of Trustees to begin developing the strategy within the financial year. The strategy was reviewed and endorsed by the Partnership Network Advisory Panel and the Board. It is available on the website at <https://genepeople.org.uk/about-us/gene-people-strategy-2022-2025/>.

Using LanguageLine

The Helpline was contacted by a non-UK patient organisation that was helping a family from Ukraine that was moving to the UK. We were able to use LanguageLine to speak with the family and suggest the best next steps so that treatment was maintained for the family member with a genetic condition.

Reaching those who need our support and information is a key priority for Gene People. To increase the **accessibility of the Helpline**, we partnered with LanguageLine, giving callers live access to translation for over 200 languages. This facility has improved the experience of enquirers to the Helpline and means that we can respond to calls even if the enquirer's first language is not English.

There were 174 enquiries during the year. The work involved in responding to those enquiries included sending 268 support emails and making 156 calls taking 72.5 hours on these calls. Enquirers asked about 89 different conditions with the majority only asked about once.

We undertook social media campaigns to highlight the availability of the Helpline on Twitter and Facebook. The learnings from these campaigns will be analysed and applied to future activity. There is still more to be done to make the Helpline accessible to all. This will form part of our plans for the future.

The team conducted by the University of Exeter, who had conducted an external evaluation of the impact of the Helpline in 2020, presented the findings of that evaluation at the World Congress on Genetic Counselling The Gene People Genetic Counsellor also participated in this international event.

"Following all your help and guidance below (it was some time ago now) I pushed for the saliva sample and a few days ago finally got the results... my son has a microdeletion." - feedback from a Helpline enquirer

Updating and improving the resources on the website, especially the **Directory of Condition-Specific Groups and Charities** is ongoing. We secured funding from Roche to undertake this, without which we would not be able to progress this much needed work. The web build for the Directory has been completed, partner organisations have been invited to send their information for inclusion, and volunteers have been researching organisations that could be listed. It is anticipated that the Directory will launch in the final quarter of 2022-23.

A workshop was held with representatives from the Partnership Network to discuss potential new resources for the Gene People community. A list was compiled and will feed into plans for coming years. We are grateful for this positive input from our Partnership Network. This input ensures that we are responding to the needs of those we seek to support, and that the help we provide is both relevant and accessible.

The **Gene People Partnership Network** is vital to our work. It is free for condition-specific support groups to join and at the end of the financial year stood at 134.

In line with our strategic aims, we offered regular online events on a variety of topics and secured funding for the programme from the BIA Rare Disease Industry Group, for which we are grateful.

Our partnership with The National Council for Voluntary Organisations (NCVO) was launched for the Partnership Network, which gives organisations a discount on their first year of membership. This gives a host of benefits to organisations, including discounts on suppliers and draft documentation saving the partners in the Partnership Network money and time.

We wanted to involve partners in shaping Gene People's services and future. We established our Partnership Network Advisory Panel and recruited volunteers to serve on this from representatives of the support groups which comprise the network.

Work started on the first Leadership Symposium since 2018 with input from Trustees and the Network.

Gene People is in the privileged position to be able to seek the views from the Partnership Network and reflect those from Helpline enquirers when participating in consultations on **national policy**. Our responses to consultations are available on our website in alignment with our values of being transparent and collaborative: <https://genepeople.org.uk/about-us/national-policy/>.

We represent the views of our community at events, and are a member of a range of organisations including:

- Association of the British Pharmaceutical Industry Patient Organisation Forum
- Breaking Down Barriers
- National Institute of Health Research Clinical Reference Network: Genetics National Speciality Group
- Disabled Children's Partnership
- Genetic Alliance UK
- Steering Group of Pharma Insight Group
- Prescription Charges Coalition
- Specialised Health Care Alliance.

The team have actively contributed to events and meetings organised by these groups as speaker, chair or facilitator. In addition, Gene People has engaged actively with:

- European Rare Disease Helpline Network
- The Guide Dogs Family Team
- Liverpool Centre for Genomic Medicine
- MAP Bio HTA Conference
- Public Policy Projects: Diagnosis
- Public Policy Projects: Gene and Cell Therapies
- Rare Bone Disease Summit
- Westminster Health Forum

All of this work is not possible without the kind support of generous donors and funders. A new fundraising strategy with a focus on building long-term relationships with supporters was devised and put in place, starting with the launch of Gene People Corporate Connections for the pharmaceutical and allied industries.

Everyone at Gene People would like to take this opportunity to thank those who supported us in 2021-22:

- Alexion Pharma GmbH
- Amicus Therapeutics
- Appeal donors
- D'Oyly Carte Charitable Trust
- Great North Run and London Marathon Runners
- Hospital Saturday Fund and all the Big Give donors
- Orchard Therapeutics
- Regular givers
- Roche
- Spirit Health
- Takeda
- UK Bio Industry Association Rare Disease Industry Group
- And all those who prefer to remain anonymous.

Together, we are Gene People.

Lastly, recognising that the climate crisis will impact everyone, including the genetic conditions community Gene People serves, the Trustees agreed a new **Environmental policy** which includes a public statement in our annual report. The policy states:

Gene People acknowledges the connection between the climate and other environmental crises, as well as the major damage being caused to the world's natural eco-systems.

Gene People therefore recognises its responsibility to reduce its carbon and environmental footprints and formally commits itself to being an environmentally responsible charity.

Gene People uses a recognised online carbon footprint calculator which shows the carbon footprint for the charity was 1.53 tonnes of CO₂e.

Future Plans

The Trustees agreed the following strategic aims for 2022-23:

- Develop and implement a UK-wide marketing strategy for the Helpline, particularly through social media
- Launch the Helpline translation service to the public
- Publish refreshed Directory of Condition-Specific Groups and Organisations
- Hold regular webinars on a range of topics for the Partnership Network
- Hold the Gene People Leadership Symposium
- Launch the Gene People Partnership Network Advisory Panel
- Submit responses to consultations with input from our Partnership Network where possible
- Continue recruitment to the Gene People Corporate Connection and develop its programme of work.

These strategic aims will be supported by work on the two enablers: income generation and infrastructure.

Financial review 2021-22

- **Reserves**

On 31 March 2022, the total monies held by Gene People stood at £31,100 of which restricted funds were £6,715. Free reserves, as defined by the Charity Commission, were £24,385. Due to the restructure, the trustees reviewed and revised the long-standing reserves policy and are of the opinion it is prudent to target approximately £70,000 in reserve. This reflects the reduction in size of the charity and provides five months of average running costs, which trustees consider to be sufficient to respond to an unexpected emergency or cover costs of an orderly wind-up should that be necessary in the future.

- **Going concern**

The accounts show the anticipated further decline in income in 2021-22 following the restructure, therefore, the trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment using forecasts and budgets prepared to cover the period to March 2023.

In considering going concern for 2022-23, the trustees have assessed the probability of successfully raising the necessary funding through the new fundraising strategy and agreed that reserves could be used in this quasi-start-up phase for the reformed charity. Given the support received from corporates, funders and individuals so far, the trustees have currently assessed that the charity should not be so affected by the changes that it should not be regarded as a going concern and therefore the financial statements include no adjustment in this respect.

Structure, Governance and Management

- **Governing Document**

Gene People changed its name from Genetic Disorders UK (GDUK) in May 2021. The registered charity number (number 1141583) and company limited by guarantee (number 07564771) remained the same. Gene People is governed by its memorandum and articles of association dated 15 March 2011. The charity is controlled by its governing document, a deed of trust, and constitutes a limited company, limited by guarantee, as defined by the Companies Act 2006.

- **Trustees**

The board of trustees is responsible for the overall governance, policy and strategic direction of Gene People, and have the legal responsibility for the operations of the charity and the use of resources in accordance with the objects of the charity. The trustees who have served during the year and since the year end are set out on page 1.

The charity is governed by individuals with a broad range of skills, including biotech, operations, finance and charity management expertise. A personal perspective on what it is to be part of a family affected by a genetic condition was provided by three of the trustees during the financial year.

Trustees serve on the board for a period of three years that is renewable. New trustees are appointed by the serving trustees, considering the skills required by the board.

- Public benefit

The trustees confirm that they have complied with the duty in Section 17(5) of the Charities Act 2011 to have due regard to the guidance issued by the Charity Commission on public benefit. The charitable purpose for the charity within the meaning of the Act is enshrined within its objects, as given in the memorandum and articles of association, and the charitable objects are included in this report.

- Governance and Management

The board of trustees meets at least four times a year to review progress and policies, with additional virtual meetings via video conferencing. With the changes to the charity and the impact of the pandemic, meetings were more frequent during the year. Formal reporting by the chief executive to the trustees takes place regularly at board meetings and informally as appropriate throughout the year.

The systems of control that are designed to provide reasonable assurance against material misstatement or loss include; an annual budget approved by the trustees; regular review of financial results, budget variances and non-financial performance indicators; delegation of authority and segregation of duties; and identification and management of risks.

Staff remuneration is determined according to the level of seniority and experience. New staff are offered salaries that align with the market average. As mandated by law, all staff are offered the opportunity to join the charity's pension scheme.

- Risk management

The trustees have overall responsibility for ensuring that Gene People is managing risk in a professional, responsible and constructive manner. Trustees have considered the major risks to which the charity is exposed and have established procedures, including a risk register, to identify and manage those risks. All risks are reviewed at least twice at Board meetings during the year.

The risk register identifies the types of risks the charity may face, assessing and balancing them in terms of potential impact and likelihood of occurrence. The trustees seek to ensure that all internal controls, and in particular financial controls, comply in all respects with best practice and inter alia the guidelines issued by the Charity Commission.

The principal risks identified by trustees in the period for Gene People are:

- The charity is unable to fundraise sufficient funds and/or in a way that maintains cashflow
- Lack of investment in IT infrastructure
- Inability to meet reserves policy requirements.

Each of these key risks has a mitigation plan managed by the CEO with support from trustees.

- Covid-19 and cost of living risk

It is recognised by the trustees that the financial performance of the charity has been and will continue to be impacted by the coronavirus (Covid-19), which

was declared a global pandemic by the World Health Organisation in March 2020, and the cost of living crisis.

Trustees have managed expenditure and continue to seek ways to both further manage cost whilst increasing income from a diversity of sources.

The operating environment for Gene People is the same for all charities and Trustees are cognisant of the risks this creates for the charity.

Report of the trustees, incorporating a strategic report, approved by order of the board of trustees, as the company directors, on ...16th December 2022..... and signed on the board's behalf by:



.....
A J Kent - Trustee

**Independent Examiner's Report to the Trustees of
Gene People (Registered number: 07564771)**

Independent examiner's report to the trustees of Gene People ('the Company')

I report to the charity trustees on my examination of the accounts of the Company for the year ended 31 March 2022.

Responsibilities and basis of report

As the charity's trustees of the Company (and also its directors for the purposes of company law) you are responsible for the preparation of the accounts in accordance with the requirements of the Companies Act 2006 ('the 2006 Act').

Having satisfied myself that the accounts of the Company are not required to be audited under Part 16 of the 2006 Act and are eligible for independent examination, I report in respect of my examination of your charity's accounts as carried out under section 145 of the Charities Act 2011 ('the 2011 Act'). In carrying out my examination I have followed the Directions given by the Charity Commission under section 145(5) (b) of the 2011 Act.

Independent examiner's statement

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe:

1. accounting records were not kept in respect of the Company as required by section 386 of the 2006 Act; or
2. the accounts do not accord with those records; or
3. the accounts do not comply with the accounting requirements of section 396 of the 2006 Act other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination; or
4. the accounts have not been prepared in accordance with the methods and principles of the Statement of Recommended Practice for accounting and reporting by charities (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)).

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.



Hazel Day BSc (Hons) FCA DChA
ICAEW
Tudor John Limited
Nightingale House
46-48 East Street
Epsom
Surrey
KT17 1HQ

Date: 19th December 2022

GENE PEOPLE

**Statement of Financial Activities
for the year ended 31 March 2022**

	Notes	Unrestricted fund £	Restricted funds £	2022 Total funds £	2021 Total funds £
INCOME AND ENDOWMENTS FROM					
Donations and legacies	2	94,591	10,000	104,591	156,990
Other trading activities	3	-	-	-	513,430
Investment income	4	-	-	-	808
Total		<u>94,591</u>	<u>10,000</u>	<u>104,591</u>	<u>671,228</u>
EXPENDITURE ON					
Raising funds	5	76,537	-	76,537	377,848
Charitable activities	6				
Awareness and education		18,861	19,000	37,861	221,775
Relief		33,802	-	33,802	81,665
Grants awarded		-	-	-	207,482
Total		<u>129,200</u>	<u>19,000</u>	<u>148,200</u>	<u>888,770</u>
NET INCOME/(EXPENDITURE)		(34,609)	(9,000)	(43,609)	(217,542)
RECONCILIATION OF FUNDS					
Total funds brought forward		58,994	15,715	74,709	292,251
TOTAL FUNDS CARRIED FORWARD		<u>24,385</u>	<u>6,715</u>	<u>31,100</u>	<u>74,709</u>

GENE PEOPLE (REGISTERED NUMBER: 07564771)

**Balance Sheet
31 March 2022**

	Notes	Unrestricted fund £	Restricted funds £	2022 Total funds £	2021 Total funds £
CURRENT ASSETS					
Debtors	13	18,773	-	18,773	15,819
Cash at bank		<u>22,440</u>	<u>6,715</u>	<u>29,155</u>	<u>224,465</u>
		41,213	6,715	47,928	240,284
CREDITORS					
Amounts falling due within one year	14	(16,828)	-	(16,828)	(165,575)
NET CURRENT ASSETS		<u>24,385</u>	<u>6,715</u>	<u>31,100</u>	<u>74,709</u>
TOTAL ASSETS LESS CURRENT LIABILITIES		<u>24,385</u>	<u>6,715</u>	<u>31,100</u>	<u>74,709</u>
NET ASSETS		<u>24,385</u>	<u>6,715</u>	<u>31,100</u>	<u>74,709</u>
FUNDS	15				
Unrestricted funds				24,385	58,994
Restricted funds				<u>6,715</u>	<u>15,715</u>
TOTAL FUNDS				<u>31,100</u>	<u>74,709</u>

The charitable company is entitled to exemption from audit under Section 477 of the Companies Act 2006 for the year ended 31 March 2022.

The members have not required the company to obtain an audit of its financial statements for the year ended 31 March 2022 in accordance with Section 476 of the Companies Act 2006.

The trustees acknowledge their responsibilities for

- (a) ensuring that the charitable company keeps accounting records that comply with Sections 386 and 387 of the Companies Act 2006 and
- (b) preparing financial statements which give a true and fair view of the state of affairs of the charitable company as at the end of each financial year and of its surplus or deficit for each financial year in accordance with the requirements of Sections 394 and 395 and which otherwise comply with the requirements of the Companies Act 2006 relating to financial statements, so far as applicable to the charitable company.

The financial statements were approved by the Board of Trustees and authorised for issue on 16th December 2022 and were signed on its behalf by:



A J Kent - Trustee

The notes form part of these financial statements

GENE PEOPLE

**Cash Flow Statement
for the year ended 31 March 2022**

	Notes	2022 £	2021 £
Cash flows from operating activities			
Cash generated from operations	1	<u>(195,310)</u>	<u>(70,187)</u>
Net cash used in operating activities		<u>(195,310)</u>	<u>(70,187)</u>
 Cash flows from investing activities			
Sale of tangible fixed assets		-	(1)
Sale of fixed asset investments		-	1
Interest received		<u>-</u>	<u>808</u>
Net cash provided by investing activities		<u>-</u>	<u>808</u>
		<u> </u>	<u> </u>
Change in cash and cash equivalents in the reporting period		(195,310)	(69,379)
Cash and cash equivalents at the beginning of the reporting period		<u>224,465</u>	<u>293,844</u>
 Cash and cash equivalents at the end of the reporting period		<u><u>29,155</u></u>	<u><u>224,465</u></u>

The notes form part of these financial statements

GENE PEOPLE

**Notes to the Cash Flow Statement
for the year ended 31 March 2022**

1. RECONCILIATION OF NET EXPENDITURE TO NET CASH FLOW FROM OPERATING ACTIVITIES

	2022 £	2021 £
Net expenditure for the reporting period (as per the Statement of Financial Activities)	(43,609)	(217,542)
Adjustments for:		
Loss on disposal of fixed assets	-	1
Interest received	-	(808)
Movement in subsidiary company balance	-	20,866
(Increase)/decrease in debtors	(2,954)	56,789
(Decrease)/increase in creditors	<u>(148,747)</u>	<u>70,507</u>
Net cash used in operations	<u>(195,310)</u>	<u>(70,187)</u>

2. ANALYSIS OF CHANGES IN NET FUNDS

	At 1.4.21 £	Cash flow £	At 31.3.22 £
Net cash			
Cash at bank	<u>224,465</u>	<u>(195,310)</u>	<u>29,155</u>
	<u>224,465</u>	<u>(195,310)</u>	<u>29,155</u>
Total	<u>224,465</u>	<u>(195,310)</u>	<u>29,155</u>

The notes form part of these financial statements

GENE PEOPLE

Notes to the Financial Statements for the year ended 31 March 2022

1. ACCOUNTING POLICIES

BASIS OF PREPARING THE FINANCIAL STATEMENTS

The financial statements of the charitable company, which is a public benefit entity under FRS 102, have been prepared in accordance with the Charities SORP (FRS 102) 'Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019)', Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006. The financial statements have been prepared under the historical cost convention, with the exception of investments which are included at market value.

CRITICAL ACCOUNTING JUDGEMENTS AND KEY SOURCES OF ESTIMATION UNCERTAINTY

Estimates and judgements are continually evaluated and are based on historical experience and other factors including expectations of future events that are believed to be reasonable under the circumstances.

The items in the financial statements where these judgements and estimates have been made include:

- estimating the useful economic life of tangible fixed assets for the purposes of determining the annual depreciation charge;
- determining the basis for allocating support costs across expenditure classifications

INCOME

Income is recognised in the period in which the charity has entitlement to the income and the amount can be measured reliably and it is probable that the income will be received. Income is deferred only when the charity has to fulfil conditions before becoming entitled to it or where the donor or funder has specified that the income is to be expended in a future accounting period. Income comprises donations, legacies, grants in respect of core funding, income from the main charitable activity, Jeans for Genes, merchandise sales and interest receivable.

Donations and grants in respect of charitable activities are recognised when the charity has confirmation of both the amount and settlement date. In the event of amounts pledged but not received, the amount is accrued for where the receipt is considered probable. In the event that a donation or grant subject to conditions that require a level of performance before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met or the fulfilment of those conditions is wholly within the control of the charity and it is probable that those conditions will be fulfilled in the reporting period

Legacies are included in the statement of financial activities when the charity is entitled to the legacy, the executors have established that there are sufficient surplus assets in the estate to pay the legacy and any conditions attached to the legacy are within the control of the charity.

Entitlement is taken as the earlier of the date on which either: the charity is aware that probate has been granted; the estate has been finalised and notification has been made by the executor to the charity that a distribution will be made; when a distribution is received from the estate. Receipt of a legacy, in whole or in part, is only considered probable when the amount can be measured reliably and the charity has been notified of the executor's intention to make a distribution.

Where legacies have been notified to the charity or the charity is aware of the granting of probate, but the criteria for income recognition have not been met, then the legacy is treated as a contingent asset and disclosed if material. In the event that the gift is in the form of an asset other than cash or a financial asset traded on a recognised stock exchange, recognition is subject to the value of the gift being reliably measurable with a degree of reasonable accuracy and the title of the asset having been transferred to the charity.

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the charity; this is normally upon notification of the interest paid or payable by the bank.

GENE PEOPLE

Notes to the Financial Statements for the year ended 31 March 2022

1. ACCOUNTING POLICIES - continued

EXPENDITURE

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be measured reliably.

Expenditure is accounted for on an accruals basis, exclusive of any VAT which is recoverable. Direct costs attributable to a single activity are allocated directly to that activity. Shared costs, which contribute to more than one activity, and support costs, which are not attributable to a single activity, are apportioned between those activities on a basis consistent with the use of resources.

Governance costs include the costs incurred in the governance of the charity and are primarily associated with constitutional and statutory requirements.

Expenditure is only deferred when it relates to future years.

Grants awarded are recognised when the offer and amount of the grant is conveyed to the beneficiary. Grants are paid in furtherance of the charitable objective of the charity.

All expenditure is inclusive of irrecoverable VAT.

Grants offered subject to conditions which have not been met at the year end date are noted as a commitment but not accrued as expenditure.

RELATED PARTY EXEMPTION

The charitable company has taken advantage of exemption, under the terms of Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', not to disclose related party transactions with wholly owned subsidiaries within the group.

TAXATION

The charity is exempt from corporation tax on its charitable activities.

FUND ACCOUNTING

Unrestricted funds can be used in accordance with the charitable objectives at the discretion of the trustees.

Restricted funds can only be used for particular restricted purposes within the objects of the charity. Restrictions arise when specified by the donor or when funds are raised for particular restricted purposes. The costs of raising and administering such funds are charged against the specific fund.

Further explanation of the nature and purpose of each fund is included in the notes to the financial statements.

GOING CONCERN

The accounts show the anticipated further decline in income in 2021-22 following the restructure, therefore, the trustees have assessed whether the use of the going concern assumption is appropriate in preparing these financial statements. The trustees have made this assessment using forecasts and budgets prepared to cover the period to March 2023.

In considering going concern for 2022-23, the trustees have assessed the probability of successfully raising the necessary funding through the new fundraising strategy and agreed that reserves could be used in this quasi-start-up phase for the reformed charity. Given the support received from corporates, funders and individuals so far, the trustees have currently assessed that the charity should not be so affected by the changes that it should not be regarded as a going concern and therefore the financial statements include no adjustment in this respect.

GENE PEOPLE

Notes to the Financial Statements - continued for the year ended 31 March 2022

BASIS OF CONSOLIDATION

The Statement of financial activities (SoFA) and balance sheet consolidated the financial statements of the charity and its subsidiary undertaking. The results of the subsidiary are consolidated on a line by line basis. No separate SoFA has been presented for the charity alone as permitted by section 408 of the Companies Act 2006.

FINANCIAL INSTRUMENTS

The charity only has financial assets and financial liabilities of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans, which are subsequently measured at amortised cost using the effective interest method.

2. DONATIONS AND LEGACIES

	2022	2021
	£	£
Donations	<u>104,591</u>	<u>156,990</u>

3. OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Charitable activities	<u>-</u>	<u>513,430</u>

4. INVESTMENT INCOME

	2022	2021
	£	£
Deposit account interest	<u>-</u>	<u>808</u>

5. RAISING FUNDS

OTHER TRADING ACTIVITIES

	2022	2021
	£	£
Jeans for Genes Day	-	223,915
Staff costs	62,072	112,052
Promotional items	14,465	41,731
Corporate partnerships: Licensing and sponsorship	<u>-</u>	<u>150</u>
	<u>76,537</u>	<u>377,848</u>

6. CHARITABLE ACTIVITIES COSTS

	Direct Costs	Support costs (see note 8)	Totals
	£	£	£
Awareness and education	7,737	30,124	37,861
Relief	<u>-</u>	<u>33,802</u>	<u>33,802</u>
	<u>7,737</u>	<u>63,926</u>	<u>71,663</u>

GENE PEOPLE

**Notes to the Financial Statements - continued
for the year ended 31 March 2022**

7. GRANTS PAYABLE

	2022	2021
	£	£
Grants awarded	<u>-</u>	<u>207,482</u>

The total grants paid to institutions during the year was as follows:

	2022	2021
	£	£
Dingley's Promise	-	3,416
FOP Friends	-	3,416
Jessie May	-	3,416
Kleefstra Syndrome	-	3,416
Newlife (Foundation for Disabled Children)	-	3,416
Glasgow Children's Hospital Charity	-	3,416
Immunodeficiency	-	123,095
48XXYY Family Support Group UK	-	3,416
Acrodysostosis Support	-	3,416
AKU Society	-	3,417
Child Growth Foundation	-	3,417
Down Syndrome Training and Support Service Ltd	-	3,417
The Fragile X Society	-	3,417
Local families with bleeding disorders	-	3,417
My Aware	-	3,417
The Neurofibromatosis Association	-	3,417
Ring20 Research and Support UK CIO	-	3,417
Scottish Huntington's Association	-	3,417
SIBS	-	3,417
The Ataxia Telangiectasia Society	-	3,417
Muscle Help Foundation	-	3,417
Rainbow Trust Children's Charity	-	3,417
Tuberous Sclerosis Association	-	3,417
Zoe's Place Trust re Coventry	-	3,417
Zoe's Place Trust re Liverpool	-	3,417
	<u>-</u>	<u>205,095</u>

8. SUPPORT COSTS

	Management Totals	Governance costs	
	£	£	£
Awareness and education	21,942	8,182	30,124
Relief	<u>33,802</u>	<u>-</u>	<u>33,802</u>
	<u>55,744</u>	<u>8,182</u>	<u>63,926</u>

9. NET INCOME/(EXPENDITURE)

Net income/(expenditure) is stated after charging/(crediting):

	2022	2021
	£	£
Auditors' remuneration	-	2,250
Deficit on disposal of fixed assets	<u>-</u>	<u>1</u>

GENE PEOPLE

Notes to the Financial Statements - continued for the year ended 31 March 2022

10. TRUSTEES' REMUNERATION AND BENEFITS

There were no trustees' remuneration or other benefits for the year ended 31 March 2022 nor for the year ended 31 March 2021.

TRUSTEES' EXPENSES

There were no trustees' expenses paid for the year ended 31 March 2022 nor for the year ended 31 March 2021.

11. STAFF COSTS

Staff costs were as follows:

	2022	2021
	£	£
Wages and salaries	105,056	270,789
Social security costs	5,784	15,778
Other pension costs	<u>6,976</u>	<u>12,698</u>
	<u>117,815</u>	<u>383,010</u>

The average monthly number of employees during the year was as follows:

	2022	2021
Fundraising	1	1
Charitable	2	2
Administration/ management	<u>-</u>	<u>1</u>
	<u>3</u>	<u>4</u>

The number of employees whose employee benefits (excluding employer pension costs) exceeded £60,000 was:

	2022	2021
£60,001 - £70,000	1	-
£100,001 - £200,000	<u>-</u>	<u>1</u>
	<u>1</u>	<u>1</u>

The aggregate employee benefits paid to key management personnel were £65,890 (2021: £104,427), the key management personnel figures include external contractors in key positions.

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES

	Unrestricted fund £	Restricted funds £	Total funds £
INCOME AND ENDOWMENTS FROM			
Donations and legacies	144,990	12,000	156,990
Other trading activities	513,430	-	513,430
Investment income	<u>808</u>	<u>-</u>	<u>808</u>
Total	<u>659,228</u>	<u>12,000</u>	<u>671,228</u>

GENE PEOPLE

**Notes to the Financial Statements - continued
for the year ended 31 March 2022**

12. COMPARATIVES FOR THE STATEMENT OF FINANCIAL ACTIVITIES - continued

	Unrestricted fund £	Restricted funds £	Total funds £
EXPENDITURE ON			
Raising funds	377,848	-	377,848
Charitable activities			
Awareness and education	210,244	11,531	221,775
Relief	81,665	-	81,665
Grants awarded	<u>207,482</u>	<u>-</u>	<u>207,482</u>
Total	<u>877,239</u>	<u>11,531</u>	<u>888,770</u>
NET INCOME/(EXPENDITURE)	(218,011)	469	(217,542)
RECONCILIATION OF FUNDS			
Total funds brought forward	277,005	15,246	292,251
TOTAL FUNDS CARRIED FORWARD	<u>58,994</u>	<u>15,715</u>	<u>74,709</u>

13. DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade debtors	10,185	-
Other debtors	11	-
VAT	6,252	15,819
Prepayments and accrued income	<u>2,325</u>	<u>-</u>
	<u>18,773</u>	<u>15,819</u>

14. CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR

	2022 £	2021 £
Trade creditors	1,181	34,711
Social security and other taxes	3,057	2,168
Other creditors	9,530	125,421
Accruals and deferred income	<u>3,060</u>	<u>3,275</u>
	<u>16,828</u>	<u>165,575</u>

GENE PEOPLE

Notes to the Financial Statements - continued
for the year ended 31 March 2022

15. MOVEMENT IN FUNDS

	At 1.4.21 £	Net movement in funds £	At 31.3.22 £
Unrestricted funds			
General fund	58,994	(34,609)	24,385
Restricted funds			
Roald Dahl's MCC	6,715	-	6,715
GDUK Helpline	<u>9,000</u>	<u>(9,000)</u>	<u>-</u>
	<u>15,715</u>	<u>(9,000)</u>	<u>6,715</u>
TOTAL FUNDS	<u><u>74,709</u></u>	<u><u>(43,609)</u></u>	<u><u>31,100</u></u>

Net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	94,591	(129,200)	(34,609)
Restricted funds			
GDUK Helpline	<u>10,000</u>	<u>(19,000)</u>	<u>(9,000)</u>
TOTAL FUNDS	<u><u>104,591</u></u>	<u><u>(148,200)</u></u>	<u><u>(43,609)</u></u>

Comparatives for movement in funds

	At 1.4.20 £	Net movement in funds £	At 31.3.21 £
Unrestricted funds			
General fund	277,005	(218,011)	58,994
Restricted funds			
PID UK	8,531	(8,531)	-
Roald Dahl's MCC	6,715	-	6,715
GDUK Helpline	<u>-</u>	<u>9,000</u>	<u>9,000</u>
	<u>15,246</u>	<u>469</u>	<u>15,715</u>
TOTAL FUNDS	<u><u>292,251</u></u>	<u><u>(217,542)</u></u>	<u><u>74,709</u></u>

GENE PEOPLE

Notes to the Financial Statements - continued for the year ended 31 March 2022

15. MOVEMENT IN FUNDS - continued

Comparative net movement in funds, included in the above are as follows:

	Incoming resources £	Resources expended £	Movement in funds £
Unrestricted funds			
General fund	659,228	(877,239)	(218,011)
Restricted funds			
PID UK	3,000	(11,531)	(8,531)
GDUK Helpline	<u>9,000</u>	<u>-</u>	<u>9,000</u>
	<u>12,000</u>	<u>(11,531)</u>	<u>469</u>
TOTAL FUNDS	<u><u>671,228</u></u>	<u><u>(888,770)</u></u>	<u><u>(217,542)</u></u>

16. EMPLOYEE BENEFIT OBLIGATIONS

The charity operates a defined contribution pension scheme. The assets of the scheme are held separately from those of the charity in independently administered funds. The pension costs charge represents contributions payable by the group to the funds and amounted to £6,976 (2021: £12,698). Contributions totalling £835 (2021: £870) were payable to the funds at the year end and are included in creditors. The expense and liability have been recognised in unrestricted funds.

17. RELATED PARTY DISCLOSURES

A licence fee was paid annually to the Chronic Granulomatous Disorder Society (CGD Society) up until the 31 March 2021, which owned the Jeans for Genes and Genetic Disorders UK (GDUK) trademarks. The fee totalled NIL (2021: £61,138).

In addition there was a SLA between Genetic Disorders UK and Chronic Granulomatous Disorder Society in relation to the provision of staff, up until the 31st March 2021. The charge for the year amounted to £NIL (2021 £13,403).

18. COMPANY STATUS

The charity is a private company limited by guarantee. The members of the company are the trustees named on page 1. In the event of the charity being wound up the liability in respect of the guarantee is limited to £1 per member of the charity.